Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | Zendy

John J.V. McMurray | Zendy; Milton Packer | Zendy; Akshay S. Desai | Zendy; Jianjian Gong | Zendy; Martin Lefkowitz | Zendy; Adel R. Rizkala | Zendy; Jean L. Rouleau | Zendy; Victor Shi | Zendy; Scott D. Solomon | Zendy; Karl Swedberg | Zendy; Michael R. Zile | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

Author(s) -

John J.V. McMurray,

Milton Packer,

Akshay S. Desai,

Jianjian Gong,

Martin Lefkowitz,

Adel R. Rizkala,

Jean L. Rouleau,

Victor Shi,

Scott D. Solomon,

Karl Swedberg,

Michael R. Zile

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1409077

Subject(s) - enalapril , neprilysin , heart failure , sacubitril , medicine , ejection fraction , cardiology , renin–angiotensin system , angiotensin ii receptor type 1 , valsartan , angiotensin receptor , angiotensin ii , angiotensin converting enzyme , endocrinology , pharmacology , chemistry , receptor , blood pressure , enzyme , biochemistry

We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research